The rapid pace of digital innovation has laid bare a growing divide between digital health and pharmaceutical commercial teams, according to a new analysis. The piece argues that pharma is missing out on the chance to significantly improve its commercial model by concentrating on incremental efficiencies rather than pursuing more fundamental reinvention.
The analysis suggests that while digital health has embraced transformation, pharma commercial teams remain focused on optimising existing processes. This approach, it contends, leaves the industry unable to fully capitalise on what digital innovation could offer.
To close the gap, the article implies that life sciences commercial leaders need to shift their mindset from efficiency gains to bolder, more innovative strategies. The source does not offer specific case studies or data, but frames the issue as a strategic blind spot for the sector.